Pancreatic Cancer Research

ResearcherLyon 1 UniversitéNo recent work listed

Mounira Chalabi‐Dchar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4539-589X; OpenAlex author ID A5000354383. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers

Papers 4

  1. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Co-author DOI 10.3390/cancers14174265↗
  2. Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265. Co-author DOI 10.3390/cancers14246160↗
  3. Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13122986↗
  4. Nucleolin Aptamer N6L Reprograms the Translational Machinery and Acts Synergistically with mTORi to Inhibit Pancreatic Cancer Proliferation. Co-author DOI 10.3390/cancers13194957↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Philippe Bouvet · 4 shared papers, 2021–2022 · strength 0.49
  2. Ilaria Cascone · 4 shared papers, 2021–2022 · strength 0.49
  3. Anaïs Debesset · 3 shared papers, 2021–2022 · strength 0.34
  4. Matteo Ponzo · 3 shared papers, 2021–2022 · strength 0.34
  5. José Laurent Cohen · 3 shared papers, 2021–2022 · strength 0.34
  6. Fabio Raineri · 3 shared papers, 2021–2022 · strength 0.34
  7. Rémy Nicolle · 2 shared papers, 2022 · strength 0.23
  8. Corinne Bousquet · 2 shared papers, 2022 · strength 0.23
  9. Christophe Tournigand · 2 shared papers, 2022 · strength 0.23
  10. Jerome F. Cros · 1 shared paper, 2021 · strength 0.11
  11. Anne Couvelard Benveniste · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.